Exhibit 10.14[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securitiesand Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.MANUFACTURING AND SUPPLY AGREEMENTDATED AS OF January 1, 2013BETWEENVAPOTHERM, INC.ANDMEDICA, S.p.A.TABLE OF CONTENTSPageARTICLE 1 SALE AND PURCHASE11.1 Supply of Cartridge11.2 [ ]11.3 Purchase of Cartridge1ARTICLE 2 FORECASTS; INVENTORY12.1 Rolling Forecasts12.2 Inventory2ARTICLE 3 ORDERS, SHIPMENT, AND PAYMENT23.1 Price23.2 Purchase Orders23.3 Delivery33.4 [ ]33.5 Delay in Delivery33.6 Delivery Default Rights33.7 Invoices and Payment Terms33.8 Delay in Payment4ARTICLE 4 QUALITY OF THE CARTRIDGE44.1 Conformity with Specifications44.2 Conditions to Rejection44.3 Rejection44.4 Nonconformity Default Rights54.5 Acceptance of Cartridges54.6 Quality Monitoring5ARTICLE 5 PRODUCTION PROCESS55.1 Joint Review Committee55.2 Process Development55.3 Inventory of Raw Materials and Spare Parts55.4 [ ]5-i-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.ARTICLE 6 QUALITY SYSTEM66.1 General Quality Statement66.2 Quality System Changes66.3 Vendor Quality66.4 Vigilance System6ARTICLE 7 OTHER OBLIGATIONS OF MEDICA77.1 Debarment Certification77.2 Permits and Certifications77.3 Manufacturing Problems77.4 Insurance7ARTICLE 8 INSPECITONS; RECORDS88.1 Notification of Inquiries and Inspections88.2 Access to Medica Facilities and Records88.3 Records9ARTICLE 9 CARTRIDGE RECALLS99.1 Cartridge Recalls99.2 Notice of Events that May Lead to Cartridge Recall99.3 Recall Due to Breach By Medica99.4 Definition of Recall99.5 Recall Process10ARTICLE 10 PUBLICITY; CONFIDENTIALITY; INTELLECTUAL PROPERTY1010.1 Publicity1010.2 Confidentiality1010.3 Pre-existing and Independently Developed Intellectual Property1110.4 Ownership1110.5 [ ]1110.6 Reservation of All Other Rights11ARTICLE 11 REPRESENTATIONS1211.1 Representations of Medica12-ii-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.11.2 Representations of Vapotherm13ARTICLE 12 INDEMNIFICATION1312.1 Indemnification1312.2 Procedures Relating to Indemnification1412.3 No Liability for Consequential Damages1512.4 Limitation on Liability15ARTICLE 13 TERM AND TERMINATION; BUSINESS CONTINUITY1513.1 Term1513.2 Termination1613.3 Effect of Termination1713.4 Business Continuity17ARTICLE 14 MISCELLANEOUS1814.1 Definitions1814.2 Further Assurances2114.3 Governing Law2114.4 Dispute Resolution2114.5 Arbitration2214.6 Force Majeure2214.7 Assignment2214.8 Notices2214.9 Severability2314.10 Entire Agreement2314.11 Amendment2314.12 Independent Contractor2314.13 Counterparts2314.14 Compliance with Laws24-iii-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.MANUFACTURING AND SUPPLY AGREEMENTThis Manufacturing and Supply Agreement (this “Agreement”) is dated January 1st, 2013, between VAPOTHERM, INC., a Maryland corporation(“Vapotherm”) and MEDICA S.p.A., an Italian company (“Medica”).WHEREAS, Vapotherm sells systems it has developed for delivering humidified, blended medical gas therapy (the “System”), which systemincludes a vapor transfer cartridge;WHEREAS, Vapotherm and Medica wish for Medica to manufacture [ ] (each, a “Cartridge” and collectively, the “Cartridges”) for Vapothermfor use in the System, using fiber provided by Medica as developed for the System and packaged as specified in Vapotherm Specification Exhibit D.NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which havehereby acknowledged, the parties therefore agree as follows:ARTICLE 1SALE AND PURCHASE1.1 Supply of Cartridge. Subject to the terms of this Agreement, Medica shall manufacture, in such quantities as Vapotherm orders, the Cartridge.1.2 [ ]1.3 Purchase of Cartridge. Subject to the terms of this Agreement, Vapotherm shall purchase from Medica Cartridges following regulatory approval.ARTICLE 2FORECASTS; INVENTORY2.1 Rolling Forecasts.Attached hereto and incorporated herein by reference as Exhibit A-2 is Vapotherm’s initial forecast of Cartridges that Vapotherm will purchase for deliveryon a monthly basis in calendar year 2013 (the “Initial Forecast”). On or prior to January 1, 2013 (the “Forecast Initiation Date”), Vapotherm shall deliverto Medica a forecast of Cartridge demand in each of the [ ] consecutive months beginning one month following the FID. On or prior to one monthfollowing the FID, Vapotherm shall provide a forecast for the next [ ] consecutive months beginning [ ] months following the FID. On or prior tothe first day of each subsequent month, Vapotherm shall deliver to Medica an update to its previously submitted forecast of its expected purchases ofCartridges (each forecast delivered pursuant to this Section 2.l(a), a “Rolling Forecast”).[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.(a) Vapotherm will place a firm Purchase Order for the following [ ] months. Every month there after, Vapotherm will placed a PO for thefollowing month to maintain a rolling [ ] month commitment.(b) The forecast for any month specified in any Rolling Forecast may not be less than the total number of Cartridges for which Vapotherm,prior to delivery of that Rolling Forecast to Medica in accordance with Section 2.l(a), has submitted purchase orders in accordance with Section 3.2specifying a delivery date in that month.2.2 Inventory.During the Term, Medica shall at all times maintain as safety stock that quantity of Cartridges equal to one (1) times the monthly average number ofCartridges ordered by Vapotherm during the immediately preceding [ ] months.ARTICLE 3ORDERS, SHIPMENT, AND PAYMENT3.1 Price. The price paid by Vapotherm for any given shipment of Cartridges during the Initial Term is as stated in Exhibit A-1. No later than [ ]days prior to the end of the Initial Term and each Renewal Term, Medica shall provide Vapotherm with reasonable documentation of its actual and directcosts in manufacturing the Cartridges (the “Costs”). The parties will then negotiate in good faith the Cartridge prices for the subsequent3.2 Purchase Orders.(a) Each purchase order that Vapotherm places for Cartridges must be in the form attached as Exhibit B and must specify (1) how manyCartridges are desired, (2) the one or more places to which, and the manner and date by which, delivery is to be made, and (3) the applicable price perCartridge. Vapotherm shall deliver all purchase orders by facsimile, or by one of the means specified in Section 14.8 for giving notice, to Medica at thefollowing address and facsimile number or as otherwise instructed by Medica:Medica S.p.A.Via Degli Artigiani, 741036 Medolla (MO) ItalyAttention: Daniele GiubertoniMKTG Sales ManagerFacsimile: 39-0535-52605E-mail: daniele.giubertonimedica.it(b) Vapotherm shall order for delivery in any given month an aggregate number of Cartridges equal to at least [ ]% of the final amountforecast for that month in the Rolling Forecasts (that quantity, the “Final Forecast Quantity”). Vapotherm may order for delivery in any given Quarter anaggregate quantity of Cartridge not exceeding [ ]% of the Final Forecast Quantity. Only with Medica’s written consent may Vapotherm order fordelivery in any given Quarter an aggregate number of Cartridges exceeding [ ]% of the aggregate Final Forecast Quantity for the months in suchQuarter.-2-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.(c) Vapotherm shall deliver each purchase order for quantities of the Cartridge at least [ ] in advance of the delivery date specified in thatpurchase order.(d) If Vapotherm delivers any purchase order with less lead time than is required under Section 3.2(c), then Medica shall use [ ] efforts tofill that purchase order but will not be liable to Vapotherm if despite those best efforts they fail to do so.(e) Medica shall acknowledge and accept in writing on behalf of Medica any purchase order that Vapotherm places for Cartridges. Any suchpurchase order will be deemed accepted by Medica if Medica does not reject it by written notice to Vapotherm delivered within [ ] Business Days ofMedica’s receiving that purchase order. Medica may not reject any purchase order that complies with the provisions of Article 3. If the terms of anypurchase are inconsistent with the terms of this Agreement, the terms of this Agreement will control.3.3 Delivery. Each shipment of Cartridges will be delivered by [ ] to the applicable Vapotherm manufacturing facility or retained in Medica’swarehouse facility, in accordance with Vapotherm instructions for each shipment. Medica shall deliver by the delivery date specified in a purchase orderall of the Cartridges specified in that purchase order. Vapotherm is only required to pay for Cartridges actually delivered. Medica shall make shippingarrangements with carriers designated in writing by Vapotherm from the [ ] point to points specified by Vapotherm, under the arrangements thatVapotherm has with those carriers.3.4 [ ]3.5 Delay in Delivery. If for any reason other than an Event of Force Majeure, Medica delivers any shipment of Cartridges later than the date ofdelivery set out in the applicable purchase order, Vapotherm will be entitled to the following as an alternative, in its sole discretion, to its rights underSection 3.6 and Section 13.2(a):(1) a [ ]% reduction in the price of each Cartridge in the shipment for every [ ] the shipment is delayed (from the Required Ship Datespecified in the Purchase Order) to a maximum of [ ]%.3.6 Delivery Default Rights. If more than [ ] days have passed since the delivery date for any Cartridges and Medica has, for any reason otherthan an Event of Force Majeure, failed to deliver those Cartridges, then, in addition to any other remedies it might have under this Agreement or by law,Vapotherm may cancel that purchase order or the portion thereof relating to those cartridges, as applicable.3.7 Invoices and Payment Terms. On delivery by Medica of a shipment of Cartridges in accordance with Section 3.3, Medica shall issue toVapotherm an invoice for that shipment stating a price consistent with the terms of this Agreement. Vapotherm shall pay each such invoice in full within[ ] Calendar Days from the date of invoice, unless Vapotherm has rejected the shipment in question in accordance with Section 4.2.-3-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.3.8 Delay in Payment. Upon delay of payment beyond [ ] days from invoice date, Medica at its’ sole discretion may levy an increase to the nettransfer price a [ ]% per week to a maximum of [ ]%.ARTICLE 4QUALITY OF THE CARTRIDGE4.1 Conformity with Specifications. Any Cartridges that Medica manufactures under this Agreement must conform to the specifications in Exhibit D(the “Specifications”) and (2) be manufactured, labeled, packaged, stored, and tested (while in the possession of, stored by, or under the control ofMedica) in accordance with cGMP. Medica shall provide adequate packaging for protection during normal shipping and handling environments.4.2 Conditions to Rejection. In order to be entitled to reject any Cartridge, Vapotherm must notify Medica of any failure of the Cartridge to meet theSpecifications or otherwise comply with this Agreement. Misuse or improper storage will not be grounds for rejection.4.3 Rejection. Vapotherm may reject any Cartridge that does not meet the Specifications or otherwise comply with this Agreement (any suchCartridge, a “Nonconforming Cartridge”). If Medica accepts that Vapotherm was entitled to reject the Nonconforming Cartridge(s) and Vapotherm hasalready paid the purchase price for the Nonconforming Cartridge(s), then, within [ ] Calendar Days after receiving notice from Vapotherm underSection 4.2, Medica shall, at Vapotherm’s election, either replace the Nonconforming Cartridge(s) at no additional cost to Vapotherm or reimburseVapotherm for the purchase price of the Nonconforming Cartridge(s) via wire transfer. Further, if Medica accepts that Vapotherm was entitled to reject theNonconforming Cartridge(s) and Vapotherm has not already paid the purchase price for the Nonconforming Cartridge(s), then, within [ ] CalendarDays after receiving notice from Vapotherm under Section 4.2, Medical shall, at Vapotherm’s election, either replace the Nonconforming Cartridge(s) at noadditional to Vapotherm beyond the original purchase price charged to Vapotherm for the Nonconforming Cartridge(s) or cancel that purchase order or theportion thereof relating to the Nonconforming Cartridge(s), s applicable.(b) If Medica does not agree that one or more Cartridges constitute Nonconforming Cartridges, the Joint Review Committee, consisting ofquality assurance representatives from both companies, must consider the matter. If after consideration by the Joint Review Committee the parties areunable to reach agreement within [ ] Calendar Days after the date Medica received notice from Vapotherm under Section 4.2, they shall submit thedispute to arbitration in accordance with Section 14.5.-4-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.4.4 Nonconformity Default Rights. If for any reason other than an event of Force Majeure Medica (1) fails to replace any Nonconforming Cartridgeas required by Section 4.3 or (2) fails to replace any Nonconforming Cartridge within [ ] Business Days after a dispute regarding whether any rejectedquantity of Cartridge constitutes Nonconforming Cartridge is decided in Vapotherm’s favor, then, in addition to any other remedies it might have underthis Agreement or by law, Vapotherm may cancel that purchase order or the portion thereof of relating to the Nonconforming Cartridge, as applicable.4.5 Acceptance of Cartridges. If Vapotherm does not notify Medica that one or more Cartridges do not meet the Specifications or otherwise fail tocomply with this Agreement, those Cartridges will be deemed to have been accepted by Vapotherm as being fully compliant with the Specifications andthis Agreement.4.6 Quality Monitoring. Medica will periodically sample and trend the Cartridge performance in accordance with specification and Medica’s internalproduction tests to monitor process and product control. Medica will share the results with Vapotherm as part of the Production Process as outlined inArticle 5.4.7 If Medica becomes aware of any Cartridge problem that could endanger patient health, Medica will report the problem to Vapotherm within 24hours.ARTICLE 5PRODUCTION PROCESS5.1 Joint Review Committee. The parties shall establish and hold teleconference meetings of a Joint Review Committee annually. The Joint ReviewCommittee shall consist of six (6) members, including the head of each party’s engineering, quality assurance and material management divisions or theirdesignees.5.2 Process Development. Medica shall use [ ] efforts to develop technical know-how that would permit them to manufacture the Cartridge lessexpensively and shall no less than semiannually furnish the Joint Review Committee with a detailed report as to their progress in this area. Vapotherm andMedica shall at the time of each report determine jointly the actions to be taken with respect to these findings.5.3 Inventory of Raw Materials and Spare Parts. Medica shall at all times use best efforts to efficiently manage their inventories of raw materials soas to enable Medica to meet Vapotherm’s demand as specified in the Rolling Forecasts. Medica shall also maintain, consistent with the manufacturer’srecommendations, an inventory of spare parts of all equipment they use to manufacture the Cartridge.5.4 [ ]-5-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.ARTICLE 6QUALITY SYSTEM6.1 General Quality Statement. The Cartridges shall be manufactured, assembled and tested in compliance with (a) the Specifications, (b) Vapothermsupplied specifications and documentation; (c) relevant ISO and FDA standards, guidelines and regulations, but not limited to ISO 13485, US 21CFR 820FDA (“QSR”), EU MDD 93/43 and Canadian MDR (d) Medica’s design and manufacturing policies followed by Medica as of the date hereof (“Medica’sQuality System”), and (e) applicable U.S. and foreign Laws, including but not limited to FDA standards, guidelines and regulations. During the Term andnotwithstanding Section 6.2 below, Medica shall not make any material change to the Specifications or Medica’s Quality System without Vapotherm’sprior written approval. For purposes of this Section 6.1, a material change to either the Specifications or Medica’s Quality System shall mean any changethat could have a material adverse effect on the safety or efficacy of the Cartridges or System, or that would be reasonably likely to have a material effecton the proper integration of the Cartridges or System.6.2 Quality System Changes. Any changes to the status of the Medica Quality System shall be reported to Vapotherm Quality Assurance andVapotherm Executive Management by sending notice in accordance with Section 14.8 within 72 hours. Status changes may include, but not be limited tothe following:(a) ISO Certifications or CE Marking status charges;(b) Process or material failures, including significant vendor related failures or relevant vendor terminations due to quality related issues; and(c) Specification changes for supplemental manufacturing processes, equipment, or materials.6.3 Vendor Quality. The quality ratings of vendors that supply Medica with materials used in the manufacture/assembly and/or testing of theCartridges shall be reported to Vapotherm Quality Assurance in a manner consistent with the Medica Quality System. Any collective actions, regulatoryholds, suspensions, or terminations of vendors related to the Cartridges shall be reported to Vapotherm Quality Assurance in a timely manner.6.4 Vigilance System. Vapotherm has an established Authorized Representative to communicate complaints and vigilance reports that results fromthe use of the Cartridges.(a) Complaint investigations shall be a shared process between Medica (QA, manufacturing, and engineering) and Vapotherm (QA,Manufacturing, and RD).(b) All investigation reports shall be issued jointly and in a timely manner to satisfy the requirements for vigilance reporting (whennecessary).-6-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.(c) When a complaint is determined to be a vigilance reportable event then Vapotherm shall be responsible for administering and reporting toboth Medica and the necessary competent authorities any Cartridge related vigilance incidents within [ ] days or as outlined in the VapothermQuality System.(d) Vapotherm shall copy in writing via email or facsimile to Medica Quality Assurance within 24-48 hours on all and any vigilance reporting,including health outcome, relationship between the incidents, and timeliness of reporting the vigilance incident to the Competent Authorities.ARTICLE 7OTHER OBLIGATIONS OF MEDICA7.1 Debarment Certification. Medica hereby agrees to review the United States Department of Health and Human Services Office of the InspectorGeneral and General Services Administration exclusion lists upon initially hiring and annually thereafter to ensure that any employee or managerresponsible for providing services under is not excluded from any United States Federal or State health care program. Medica hereby represents andwarrants that neither it, nor any of its officers, directors, or managers, or employees are currently excluded from, or have ever been excluded from, anyUnited States Federal or State health care program or, if previously excluded, have been fully reinstated, in which case Medica shall provide Vapothermwritten proof of such reinstatement and such other information as Vapotherm may require describing the reasons for the prior exclusion. Medica shallimmediately notify Vapotherm, in writing, in the event that it knows, or has reason to know, that any United States Federal or State health care programhas initiated proceedings to sanction, bar, suspend or exclude Medica, or any of its officers, directors, managers or employees. If Medica fails to complywith any of the foregoing provisions, Vapotherm may terminate the Agreement immediately upon written notice to Medica.7.2 Permits and Certifications. Medica currently has all Permits and Certifications necessary to enable it to perform all its obligations under thisAgreement. At all times during the Term Medica shall maintain those Permits and secure any additional Permits that become necessary.7.3 Manufacturing Problems. Medica shall promptly notify Vapotherm if it experiences any significant problems in manufacturing Cartridges, shalluse [ ] efforts to resolve those problems, and shall keep Vapotherm informed of the status of those efforts.7.4 Insurance. Medica shall at its cost obtain and maintain one or more insurance policies providing coverage of at least Euro [ ] in theaggregate that cover Medica for fire, theft, fidelity, product liability, and any and all potential claims, suits, losses, expenses, or damages arising out ofMedica’s obligations under this Agreement. At Vapotherm’s request to Medica from time to time, Medica shall furnish Vapotherm with certification ofinsurance evidencing that insurance and shall provide at least [ ] Business Days prior written notice to Vapotherm of any cancellation of or decreasein the dollar amount of coverage provided by any such policy. Vapotherm shall have the right to maintain such insurance coverage on Vapotherm’s behalfand at Vapotherm’ s expense in the event of nonpayment of premiums or lapse of coverage.-7-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.(b) Vapotherm shall at its cost obtain and maintain product-liability insurance coverage in the amount of [ ] in relation to the Cartridge.At the request of Medica from time to time, Vapotherm shall famish Medica with certification of insurance evidencing that insurance and shall endeavourto provide at least [ ] Business Days prior written notice to Medica of any cancellation of or decrease in the amount of coverage provided by anysuch policy.ARTICLE 8INSPECITONS; RECORDS8.1 Notification of Inquiries and Inspections. Medica shall notify Vapotherm within [ ] Business Days of any written or oral inquiries,notifications, or inspection activity by any Governmental Authority in regard to Medica’s manufacture of Cartridges. Medica shall permit up to twoindividuals selected by Vapotherm to attend any such inspections and shall provide Vapotherm with an accurate and reasonably complete description ofany such inquiries, notifications, or inspections. Medica shall also furnish to Vapotherm (1) within [ ] Business Days after receipt any report orcorrespondence issued by any Governmental Authority in connection with any such inquiries, notifications, or inspections, and (2) not later than [ ]Business Days prior to the time Medica proposes to send it, a copy of any proposed response or explanation relating to any such inquiries, notifications,or inspections or any report or correspondence issued by any Governmental Authority in connection therewith (each, a “Proposed Response”), in eachcase redacted of trade secrets or other confidential or proprietary information of Medica that are unrelated to Medica’s obligations under this Agreementor are unrelated to manufacture of Cartridges. Medica shall discuss with Vapotherm any Proposed Response and shall incorporate in that ProposedResponse any reasonable comments provided by Vapotherm with respect to that Proposed Response. After filing a response with any GovernmentalAuthority, Medica shall within [ ] Business Days notify Vapotherm of any further contacts with that Governmental Authority with respect to thatresponse.8.2 Access to Medica Facilities and Records. Medica shall at Vapotherm’s request give Vapotherm and any designee of Vapotherm reasonableaccess to Medica’s facilities, procedures, and books and records, including Medica’s protocols, standard operating procedures (SOPs), equipmentspecifications, and manufacturing records, for purposes of (1) observing manufacturing, operations and (2) auditing and inspecting Medica’s facilities forcompliance with applicable Laws and the terms of this Agreement. Vapotherm acknowledges that it and its designee may be permitted only to review,rather than obtain copies of, certain proprietary documents of Medica; Medica shall at Vapotherm’s request provide Vapotherm with a copy of any otherdocument that Vapotherm requests provided it is reasonable and applicable to the Cartridges or System.-8-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.8.3 Records. Medica shall maintain all records necessary to evidence compliance with all applicable Laws and other requirements of applicableGovernmental Authorities relating to the manufacture of the Cartridge. Medica shall also maintain records with respect to its costs, obligations, andperformance under this Agreement. All such records shall be maintained for a period of not less than two years from the date of expiration of eachCartridge batch to which those records pertain, or such longer period as may be required by Law or cGMPs.ARTICLE 9CARTRIDGE RECALLS9.1 Cartridge Recalls. If any Governmental Authority withdraws its approval to sell the Cartridge in any country or issues a directive or request thatsome or all Cartridges be recalled for safety reasons relating to the Cartridge or Vapotherm reasonably determines that some or all Cartridges should berecalled, and if that recall is due to any reason other than Medica having manufactured Cartridges that fail to conform to the Specifications or that wasnot manufactured in accordance with any applicable Laws, Vapotherm shall pay all costs, including Medica’s reasonable out-of-pocket expenses,associated with that recall. Those actions may include developing reports on records pertaining to the lot traceability, assist in conducting aninvestigation to rule out a root cause for failure and other related activities requiring Medica’s resources. Vapotherm shall provide Medica in writingspecific instructions as to actions required. Medical shall in good faith provide an estimate for expenses if the request has material burden.9.2 Notice of Events that May Lead to Cartridge Recall. Medica, on the one hand, and Vapotherm, on the other hand, shall keep each other fully andpromptly informed of any notification, event, or other information, whether received directly or indirectly, that might affect the marketability, safety oreffectiveness of the Cartridge or might result in a recall of any Cartridges by any Governmental Authority.9.3 Recall Due to Breach By Medica. If there occurs any Cartridge recall that is due to Medica having manufactured one or more Cartridges that failto conform to the Specifications or that were not manufactured in accordance with any applicable Laws, Medica will be responsible for the costs of thatrecall. Medica shall promptly, at the election of Vapotherm, compensate Vapotherm for the Cartridge so recalled by either replacing without chargeCartridges recalled or refunding Vapotherm the price paid by Vapotherm to Medica for the Cartridges recalled, plus freight, insurance, sales taxes, and allother costs duties, fees, and expenses paid by Vapotherm in connection with such recall.9.4 Definition of Recall. For purposes of this Article 8, “recall” means any action by Vapotherm or any of its Affiliates, or either Medica or any of itsAffiliates, to recover title or possession or halt distribution or use of any Cartridges sold or shipped to any other Persons. The term “recall” also appliesto Cartridge that would have been subject to recall if it had been sold or shipped.-9-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.9.5 Recall Process. The purpose of initiating a “recall”, either party will notify the other party immediately regarding the need within 24 hrs.Vapotherm will be responsible for notifying the appropriate regulatory bodies with respect to the Cartridge. Medica will provide best efforts to supportVapotherm with the appropriate regulatory documentation in an timely fashion. Medica will make efforts to conduct the necessary investigations as itpertains to the Cartridge and report factual data has required. Medica will also take necessary efforts to take the appropriate corrective action and makebest efforts to remedy the disruption in supply.ARTICLE 10PUBLICITY; CONFIDENTIALITY; INTELLECTUAL PROPERTY10.1 Publicity. Except as required by Law or the standards of any securities or regulatory authority, including without limitation the NationalAssociation of Securities Dealers, Medica and Vapotherm may not make any official press release, announcement, or other formal publicity relating to thetransactions that are the subject of this Agreement without first obtaining in each case the prior written consent of Vapotherm and Medica, respectively(which consent may not be unreasonably withheld). If any party is required to file this Agreement with the Securities and Exchange Commission oranother applicable securities regulatory authority, that party must seek confidential treatment for any provisions of this Agreement that either partybelieves would disclose trade secrets, confidential commercial, or financial information and thereby impair the value of the contractual rights representedby this Agreement or provide detailed commercial and financial information to competitors or other Persons. Except as required by Law or the standardsof any securities regulatory authority, Medica and Vapotherm may not use the name Vapotherm and Medica, respectively, or the name of any director,officer or employee thereof or any adaptation thereof without the prior written approval of Vapotherm and Medica, respectively.(b) Medica shall send to Vapotherm for its approval at least [ ] Business Days before it is filed or submitted any publication, abstract, orpatent application resulting from this Agreement. The authorship on any publication or abstract will be determined by agreement of the parties or asdeemed scientifically appropriate. Any publication resulting from this Agreement will be delayed or prohibited if, in Vapotherm’s reasonable opinion,delay or prohibition is required in order to file or procure patent application or rights protection in respect of any invention or discovery arising from thisAgreement. Publication by Medica of any information relating to the Cartridge is subject to the provisions of Section 10.2.10.2 Confidentiality. It is contemplated that Medica may from time to time disclose Confidential Information to Vapotherm, or vice versa. Medicashall disclose such Vapotherm Confidential Information and shall not use any Vapotherm Confidential Information other than in connection withperforming its obligations hereunder, and Vapotherm shall not disclose Medica Confidential Information and shall not use any Medica ConfidentialInformation other than in connection with performing its obligations hereunder.(b) A party receiving Confidential Information shall only disclose it to those of its Representatives who need to review that ConfidentialInformation in connection with that party’s performance of its obligations and evaluation of its rights under this Agreement. Any party who so disclosesany Confidential Information pursuant to this Section 10.2(b) shall (1) inform those Representatives of the confidential nature of that ConfidentialInformation, and (2) direct those Representatives to keep that Confidential Information confidential.-10-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.(c) The provisions of this Section 10.2 will survive termination or expiration of this Agreement and will continue for a period of 5 years fromthe date of that termination or expiration.10.3 Pre-existing and Independently Developed Intellectual Property. Each party is and shall remain the owner of its Intellectual Property inexistence as of the Effective Date and all such rights that a party acquires or develops independent of this Agreement (“Baseline IP”).10.4 Ownership.(a) Except as specified elsewhere in Section 10.4, all rights in patents, inventions, processes, discoveries, and other research materials andany other novel or valuable information reflected in any medium that arise or are created during the course of this Agreement are the property of thecreating party.(b) Any additions, improvements and enhancements to Vapotherm Baseline IP which are made during the course of this Agreement shallsolely be the property of Vapotherm (“Vapotherm Inventions”).(c) Any additions, improvements and enhancements to Medica Baseline IP which are made during the course of this Agreement shall solelybe the property of Medica (“Medica Inventions”).(d) It is understood and agreed that Vapotherm shall be free and without restriction to develop, market, license, and sell products andtechnology as it may see fit (including products and technology that may) or may not compete with the Cartridges), provided that Vapotherm strictly andfully complies with its obligations concerning Medica Confidential Information under Section 10.2 (Confidentiality).(e) It is understood and agreed that Medica shall be free and without restriction to develop, market, license, and sell products andtechnology based on Medica proprietary membrane with an intended use different from oxygen delivery humidification for patients.10.5 [ ](b) [ ]10.6 Reservation of All Other Rights. Except as expressly set forth in this Agreement, nothing contained herein may be construed as doing thefollowing:-11-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.(a) Giving Medica any rights to any Intellectual Property of Vapotherm or any other proprietary technology of Vapotherm (whether VapothermBaseline IP or Vapotherm Inventions arising in connection with this Agreement), including without limitation any of Vapotherm’s patent rights relating tothe design, development, testing, use and sale of the System or the Cartridge; or(b) Giving Vapotherm any rights to any Intellectual Property of Medica or any other proprietary technology of Medica (whether MedicaBaseline IP or Medica Inventions arising in connection with this Agreement).ARTICLE 11REPRESENTATIONS11.1 Representations of Medica. Medica represents to Vapotherm as follows:(a) Medica is a corporation validly existing under the laws of its jurisdiction of organization with the power to own all of its properties andassets and to carry on its business as it is currently being conducted.(b) Medica has the power to execute and deliver this Agreement and to perform its obligations under this Agreement.(c) Medica’s Chief Executive Officer, or Amministratore Unico (AU), has duly authorized Medica to execute and deliver this Agreement andperform its obligations under this Agreement, and no other corporate proceedings of Medica are necessary with respect thereto.(d) This Agreement constitutes its valid and binding obligation, enforceable in accordance with its terms, except as enforceability is limitedby (A) any applicable bankruptcy, insolvency, reorganization, moratorium or similar law affecting creditors’ rights generally, or (B) general principles ofequity, whether considered in a proceeding in equity or at law.(e) Medica is not required to obtain the Consent of any Person, including the Consent of any party to any Contract to which it is a party, inconnection with execution and delivery of this Agreement and performance of its obligations under this Agreement.(f) Medica is the rightful owner or licensee of any Intellectual Property that it may use in performing its obligations under this Agreement.(g) To Medica’s knowledge, the Medica Baseline IP does not infringe or violate any patent, copyright, trademark, or any other proprietaryright of a third party.(h) Medica’s execution and delivery of this Agreement and performance of its obligations under this Agreement do not (A) violate anyprovision of its articles of incorporation or by-laws, as applicable, as currently in effect, (B) conflict with, result in a breach of, constitute a default under(or an event which, with notice or lapse of time or both, would constitute a default under), accelerate the performance required by, result in the creation ofany Lien upon any of its properties or assets under, or create in any party the right to accelerate, terminate, modify, or cancel, or require any notice under,any Contract to which it is a party or by which any of its properties or assets are bound, or (C) violate any Law or Order currently in effect to which it issubject.-12-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.11.2 Representations of Vapotherm. Vapotherm represents to Medica as follows;(a) Vapotherm is a corporation validly existing and in good standing under the law of the State of Maryland with the power to own all of itsproperties and assets and to carry on its business as it is currently being conducted.(b) Vapotherm has the power to execute and deliver this Agreement and to perform its obligations under this Agreement.(c) This Agreement constitutes the valid and binding obligation of Vapotherm, enforceable in accordance with its terms, except asenforceability is limited by (A) any applicable bankruptcy, insolvency, reorganization, moratorium or similar law affecting creditors’ rights generally, or (B)general principles of equity, whether considered in a proceeding in equity or at law.(d) Vapotherm’s execution and delivery of this Agreement and performance of its obligations under this Agreement do not (A) violate anyprovision of Vapotherm’s articles of incorporation or by-laws as currently in effect, or (B) violate any Law or Order currently in effect to which Vapothermis subject.ARTICLE 12INDEMNIFICATION12.1 Indemnification. Medica shall indemnify Vapotherm, each Affiliate of Vapotherm, each Representative of Vapotherm, and the heirs, executors,successors, and assigns of any of the foregoing, against the following Indemnifiable Losses:a.Indemnifiable Losses arising out of or relating to a claim made for bodily injury, including death, or property damage to the extent that suchclaim arises out of or results from the failure of the Cartridges to comply with the Specifications or Medica’s failure to comply with Medica’sQuality System;b.Indemnifiable Losses arising out of or relating to any claim, demand, action or proceeding based upon infringement of a patent, trademark,copyright or trade secret, or similar intellectual property rights as a result of Vapotherm’s marketing, promotion or distribution of theCartridges;c.Indemnifiable Losses arising out of relating to any breach of this Agreement by Medica or any negligent or fraudulent act or willfulmisconduct of Medica or its employees, other agents, subcontractors or representatives in connection with this Agreement; or-13-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.d.Indemnifiable Losses arising out of or relating to any inaccuracy in any representations of Medica contained in this Agreement.(b) Vapotherm shall indemnify each Medica Entity, each Affiliate of each Medica Entity, each Representative of each Medica Entity, and theheirs, executors, successors, and assigns of any of the foregoing, against the following Indemnifiable Losses:(i) Indemnifiable Losses arising out of or relating to any claim, demand, action or proceeding based upon infringement of a patent,trademark, copyright or trade secret, or similar intellectual property rights as a result of Vapotherm’s marketing, promotion or distribution ofthe System, except to the extent such claim, demand, action or proceeding arising out of or relates to the Cartridge;(ii) Indemnifiable Losses arising out of or relating to any breach of this Agreement by Vapotherm or any negligent or fraudulent act orwillful misconduct of Vapotherm or its employees, other agents, subcontractors or representatives in connection with this Agreement; or(iii) Indemnifiable Losses arising out of or relating to any inaccuracy in any representations of Vapotherm contained in this Agreement.12.2 Procedures Relating to Indemnification. In order to be entitled to indemnification under this Article 12 in connection with an IndemnifiableLoss, the party seeking indemnification (the “Indemnified Party”) must:(1)notify the party obligated to indemnify it (the “Indemnifying Party”) in writing, and in reasonable detail, of any third party claims, demands,lawsuits, proceedings or action (“Third Party Claims”) as soon as possible but in any event within [ ] Business Days after receipt ofnotice of that Third Party Claim; and(2)deliver to the Indemnifying Party as soon as possible but in any event within [ ] Business Days after the Indemnified Party receives acopy of all notices and documents (including court papers) delivered to that Indemnified Party relating to that Third Party Claim.(b) In the event of a Third Party Claim against an Indemnified Party, the Indemnifying Party may participate in the defense of that Third PartyClaim and, if it so chooses, assume at its expense the defense of that Third Party Claim with counsel selected by the Indemnifying Party and reasonablysatisfactory to the Indemnified Party. If the Indemnifying Party so elects to assume the defense of a Third Party Claim, the Indemnifying Party will not beliable to the Indemnified Party for any legal expenses subsequently incurred by the Indemnified Party in connection with the defense of that Third PartyClaim, except that if, under applicable standards of professional conduct, there exists a conflict on any significant issue between the Indemnified Partymid the Indemnifying Party in connection with that Third Party Claim, the-14-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.Indemnifying Party shall pay the reasonable fees and expenses of one additional counsel to act with respect to that issue to the extent necessary toresolve that conflict. If the Indemnifying Party assumes defense of any Third Party Claim, the Indemnified Party will be entitled to participate in thedefense of that Third Party Claim and to employ counsel, at its own expense, separate from counsel employed by the Indemnifying Party, it beingunderstood that the Indemnifying Party will be entitled to control that defense. The Indemnifying Party will be liable for the fees and expenses of counselemployed by the Indemnified Party for any period during which the Indemnifying Party did not assume the defense of any Third Party Claim (other thanduring any period in which the Indemnified Party failed to give notice of the Third Party Claim as provided above and a reasonable period after suchnotice). If the Indemnifying Party chooses to defend or prosecute a Third Party Claim, all the parties shall cooperate in the defense or prosecution of thatThird Party Claim, including by retaining and providing to the Indemnifying Party records and information reasonably relevant to that Third Party Claim,and making employees available on a reasonably convenient basis. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, theIndemnified Party will agree to any settlement, compromise or discharge of that Third Party Claim that the Indemnifying Party recommends, except thatthe Indemnifying Party may not without the Indemnified Party’s prior written consent agree to entry of any judgment or enter into any settlement thatprovides for injunctive or other non-monetary relief affecting the Indemnified Party or that does not include as a unconditional term that each claimant orplaintiff give to the Indemnified Party a release from all liability with respect to that Third Party Claim. Whether or not the Indemnifying Party hasassumed the defense of a Third Party Claim, the Indemnified Party shall not admit any liability with respect to, or settle, compromise or discharge, thatThird Party Claim without the Indemnifying Party’s prior written consent.12.3 No Liability for Consequential Damages. No party will be liable to any other for any indirect, consequential, or special damages or for loss ofprofits. This limitation does not, however, apply to any obligation of either party to indemnify the other in connection with any Indemnifiable Loss.12.4 Limitation on Liability.Notwithstanding any other provision contained in this Agreement, each party’s maximum aggregate liability to the other party for any and allcauses whatsoever, and each party’s remedy, regardless of the form of action, whether in contract or tort, including negligence, and whether or notpursuant to the indemnification provisions contained in Section 12 and whether or not such party is notified of the possibility of damage to the otherparty, shall be limited to [ ].ARTICLE 13TERM AND TERMINATION; BUSINESS CONTINUITY13.1 Term. The term of this Agreement is three years from and including the date of this Agreement (the “Initial Term”), with automatic renewal foradditional successive one-year terms (each a “Renewal Term” and together wit the Initial Term, the “Term”) unless no later than [ ] days prior to theend of the Initial Term, or any Renewal Term either party notifies the other that it wishes to terminate this Agreement effective the end of the Initial Termor that Renewal Term, as applicable.-15-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.13.2 Termination. This Agreement may be terminated as follows:(1)by Vapotherm upon [ ] Business Days’ written notice to Medica if any representation made in this Agreement by Medica was materiallyinaccurate when made and either (1) that inaccuracy has contributed to Vapotherm’s incurring Indemnifiable Losses or (2) Medica fails to takeaction to render the inaccurate representation accurate as if it were made on the day Vapotherm would otherwise be entitled to terminate thisAgreement under this Section 13.2(a)(l);(2)by Medica upon [ ] Business Days; written notice to Vapotherm if any representation made in this Agreement by Vapotherm wasmaterially inaccurate when made and either (1) that inaccuracy has contributed to either or both Medica Entities’ incurring IndemnifiableLosses or (2) Vapotherm fails to take action to render the inaccurate representation accurate as if it were made on the day Medica wouldotherwise be entitled to terminate this Agreement pursuant to this Section 13.2(a)(2);(3)by Vapotherm immediately if Medica has breached any of its material obligation under this Agreement and, if it is curable, has not cured thatbreach prior to expiration of a [ ]-Business-Day period following notice of the breach from Vapotherm;(4)by Medica immediately if Vapotherm has breached any of its material obligations under this Agreement and, if it is curable, has not cured thatbreach prior to expiration of a [ ]-Business-Day period following notice of the breach from Medica;(5)by Vapotherm immediately if there occurs an Event of Insolvency with respect to Medica;(6)by Medica immediately if there occurs an Event of Insolvency with respect to Vapotherm;(7)by Vapotherm, if for any reason other than an Event of Force Majeure Medica fails to deliver within [ ] days after the required deliverydate, or on more than two occasions in any [ ]-day period fails to deliver within [ ] days after the required delivery day, any shipmentof Cartridge it is required to deliver pursuant to Section 3.2, Section 4.2, or Section 9.3; or(8)by Medica or Vapotherm on [ ] Business Days’ prior written notice to Vapotherm or Medica, respectively, if due to an Event of ForceMajeure (A) Vapotherm or (B) Medica or both of them, respectively, is prevented from performing an obligation under this Agreement formore than [ ] days, unless prior to the end of the [ ]-Business-Day period the Event of Force Majeure ceases to exist and the partyprevented from performing resumes performance under this Agreement and notifies the party giving the notice of termination.-16-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.(b)The parties may terminate this Agreement at any time by written agreement.13.3 Effect of Termination.(a) Upon any termination (including expiration) of this Agreement, each party shall return to the other party all documents and other tangibleitems to it or its employees or agents have received or created pursuant to this Agreement pertaining, referring, or relating to Confidential Information ofthe other party.(b) Termination of this Agreement will not affect rights and obligations of either party that may have accrued prior to the date of terminationor any other obligation contained in Section 5.5, 6.3, 6.4, 8.1, 8.3, Article 9, 10.1, 10.2, 10.3, 10.4, 10.5(b), 10.6, Article 12, Article 13, and Sections 14.3, 14.4,and 14.5. All rights and obligation decay after 2 (two) years from termination or expiration.(c) Upon any termination (including expiration) of this Agreement, Vapotherm shall pay to Medica, and Medica shall pay to Vapotherm, allamounts payable up to the date of termination but not yet paid.(d) The termination or expiration of this Agreement shall not relieve either party of its responsibility to comply in all material respects withany statutory or regulatory requirements associated with the System and/or the Cartridges.13.4 Business Continuity.Medica agrees to have the capability to manufacture in either (2) facilities of the Medica Group in the event of disruption for any reason and deliverthe Cartridges within [ ] weeks.13.4.1 Medica agrees to maintain [ ] weeks [ ] of inventory in the event of business disruption consistent with section 2 of the agreement.13.4.2 Notwithstanding anything to the contrary in this Agreement, Medica shall neither enter into an agreement to nor shall consummate (a) anyChange of Control or (b) any sale of all or substantially all of its assets relating to the manufacture of the Cartridges unless (a) it provides Vapothermwritten notice of any such proposed transaction, which notice shall include the specific terms and conditions of the proposed transaction, including theidentify of the proposed acquirer, (b) Medica offers to enter into such transaction with Vapotherm on substantially the same terms and conditions, and (c)with [ ] days of such notice, Vapotherm declines to accept such offer. For purposes of this Agreement, “Change of Control” means (i) the acquisition,directly or indirectly, by any person or group (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended) that is not asubsidiary or Affiliate-17-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.(as defined below) of Medica of the beneficial ownership of securities of Medica possessing more than fifty percent (50%) of the total combined votingpower of all outstanding securities of Medica; (ii) a merger or consolidation in which neither Medica nor a subsidiary or Affiliate of Medica is thesurviving entity; (iii) a reverse merger in which Medica is the surviving entity but in which securities possessing more than fifty percent (50%) of the totalcombined voting power of Medica’s outstanding securities are transferred to or acquired by a person or persons different from the persons holding thosesecurities immediately prior to such merger and where such persons are not a subsidiary or Affiliate of Medica; or (iv) the sale, transfer or otherdisposition of all or substantially all of the assets of Medica to a person or entity that is not a subsidiary or Affiliate of Medica.ARTICLE 14MISCELLANEOUS14.1 Definitions. When used in this Agreement, the following terms have the following meanings:“Affiliate” means, with respect to any given Person, any other Person at the time directly or indirectly controlling, controlled by or under commoncontrol with that Person, or (2) any director, officer or employee of that Person. For purposes of this Agreement, “control” means the possession, directlyor indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities, bycontract or otherwise.“Business Day” means any Monday, Tuesday, Wednesday, Thursday, or Friday that is not a day on which banking institutions in the State of NewYork authorized by law, regulation or executive order to close.“cGMPs” means current Good Manufacturing Practices (as provided for, respectively, in the Rules Governing Medicinal Products in the EuropeanCommunity Volume 4 (Guide to Good Manufacturing Practice for Medicinal Products) and by the FDA as set out in 21 C.F.R. 210 and 21 C.F.R. 211, asamended from time to time).“Confidential Information” means all data, specifications, training, and any other know-how related to the design, development, manufacture, orperformance of the System or the Cartridge, the customers, finances, methods, research, processes or procedures of a party, as well as all otherinformation and data provided by either party to the other party pursuant to this Agreement (i) in written or other tangible medium and marked asconfidential, or (ii) if disclosed orally or displayed, confirmed in writing within [ ] Business Days after disclosure and marked as confidential, or (iii)that by the nature of the information or the circumstances surrounding disclosure, should in good faith be treated as confidential, except that the term“Confidential Information” does not include the following:(1)information that is or becomes generally available to the public other than as a result of a breach of this Agreement by the receiving party orits Representatives;-18-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.(2)information that was within the receiving party’s possession or knowledge prior to its being furnished to the receiving party by or on behalfof the disclosing party, on condition that the source of that information was not bound by a confidentiality agreement with or othercontractual, legal or fiduciary obligation of confidentiality to the disclosing party or any other Person with respect to that information;(3)information that is or becomes available to the receiving party on a non-confidential basis from a source other than the disclosing party orany of its Representatives, on condition that that source was not bound by a confidentiality agreement with or other contractual, legal orfiduciary obligation of confidentiality to the disclosing party or any other Person with respect to that information;(4)information that is independently developed by the receiving party without use of Confidential Information and otherwise in a manner not.inconsistent -with this Agreement; or(5)information that is required to be disclosed by law, provided that the disclosing Party is promptly notified by the receiving Party in order toprovide the disclosing Party an opportunity to seek a protective order or other relief.“Consent” means any approval, consent, ratification, filing, declaration, registration, waiver, or other authorization.“Contract” means any oral or written agreement, contract, obligation, promise, arrangement, or undertaking that is legally binding.“Event of Insolvency” with respect to any Person means any of the following:(1)the institution by that Person of proceedings under the United States Bankruptcy Code, or any other applicable U.S. federal or state Law orany applicable foreign Law seeking an order for relief;(2)the consent of that Person to the institution of bankruptcy or insolvency proceedings against that Person;(3)the filing by that Person of a petition seeking reorganization or release under the Federal Bankruptcy Reform Act or any other applicable U.S.federal or state Law or applicable foreign Law, or the consent by that Person to the filing of any such petition or to the appointment of areceiver, liquidator, assignee, trustee, sequestrator (or other similar official) of that Person or of any substantial part of the property of thatPerson;(4)the making by that Person of an assignment for the benefit of creditors;-19-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.(5)admission by that Person of its inability to pay its debts generally as they become due;(6)the entry of a decree or order by a court having jurisdiction adjudging that Person bankrupt or insolvent, or approving as properly filed apetition seeking reorganization, arrangement, adjustment or composition of or in respect of that Person under the U.S. Bankruptcy Code orany other applicable U.S. federal or state Law or any applicable foreign Law, or appointing a receiver, liquidator, assignee, trustee,sequestrator (or other similar official) of that Person, or of any substantial part of the property of that Person, or ordering the winding up orliquidation of the affairs of that Person, and (A) that Person consents to that decree or order or (B) that decree or order remains unstayed andin effect for more than [ ] consecutive days.“FDA” means the U.S. Food and Drug Administration.“FOB” means “Free on Board,” as that term is defined in INCOTERMS 2000,“Governmental Authority” means any (1) nation, state, comity, city, town, village, district, or other jurisdiction of any nature, (2) federal, state, local,municipal, or other government, whether U.S. or foreign, (3) governmental or quasi-governmental authority of any nature (including any governmentalagency, branch, department, official, or entity and any court or other tribunal, including an arbitral tribunal), (4) multi-national organization or bodyincluding the EU and notified bodies, or (5) body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulator)’, ortaxing power of any nature.“Indemnifiable Losses” means all losses, liabilities, taxes, damages, deficiencies, obligations, fines, expenses, judgments or settlements resultingfrom Third Party Claims that are incurred or suffered by an Indemnified Party, including interest and penalties with respect thereto and out-of-pocketexpenses and reasonable attorneys’ and accountants’ and experts’ fees and expenses incurred in the investigation or defense of any of the same or inasserting, preserving or enforcing any of the Indemnified Party’s rights hereunder, net of any amounts recovered or recoverable under any insurancepolicy.“Intellectual Property” means, with respect to any Person, all unpatented ideas, inventions, processes, discoveries trademarks, patents,copyrights, and any applications for registration thereof, and trade secrets and know-how of that Person, whether owned, used, or licensed by thatPerson as licensee or licensor.“Law” means any federal, state, local, municipal, foreign, international, multinational, or other administrative order, constitution, law, ordinance,principle of common law, regulation, statute, or treaty.“Lien” means any charge, claim, community property interest, condition, equitable interest, lien, option, pledge, security interest, right of firstrefusal, or restriction of any kind, including any restriction on use, voting, transfer, receipt of income, or exercise of any other attribute of ownership.-20-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.“Month” means any of the twelve months of a year.“Order” means any award, decision, injunction, judgment, order, ruling, subpoena, or verdict of any court, arbitral tribunal, administrative agency,or other Governmental Authority.“Person” means any individual, corporation (including any non-profit corporation), general or limited partnership, limited liability company, jointventure, estate, trust, association, organization, labor union, Governmental Authority or other entity.“Representative” means, with respect to a particular Person, any director, officer, employee, agent, consultant, advisor, or other representative ofthat Person, including legal counsel, accountants, and financial advisors.“Year” means (1) the period commencing with the date of this Agreement and ending on November 7th 2009, (2) any subsequent 12-month periodcommencing on January 1st and ending on December 31st, and (3) the period beginning January 1st of the year in which this Agreement expires or isterminated and ending on the date this Agreement expires or is terminated.14.2 Further Assurances. At any time or from time to time from the date of this Agreement, Medica, on the one hand, and Vapotherm, on the otherhand, shall at the request, and at the expense, of the other do the following:(1)to the extent consistent with this Agreement deliver to the other such records, data, or other documents requested by the other; and(2)take or cause to be taken all such other actions as are reasonably necessary or desirable in order to permit the other to obtain the full benefitsof this Agreement.14.3 Governing Law. This Agreement is governed by the laws of the State of New York without giving effect to principles of conflict of laws.14.4 Dispute Resolution. The parties shall attempt in good faith to resolve any controversy or claim that may arise concerning their respectiverights and obligations under this Agreement. If they are unable to do so within [ ] Business Days from the date that controversy or claim arose, theyshall refer the controversy or claim to the AU of Medica and the CEO of Vapotherm, who shall meet in person or telephonically within [ ] BusinessDays of being requested to do so and shall in good faith attempt to resolve the dispute. If the controversy or claim cannot then be solved, the partieshereby agree first to try in good faith to settle the dispute by mediation administered by the American arbitration Association at its New York City officesbefore resorting to arbitration.-21-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.14.5 Arbitration. Any controversy or claim arising out of or relating to this Agreement or the applicability of this Section 14.5 that is not resolvedpursuant to Section 14.4 will be determined by arbitration in accordance with the International Arbitration Rules of the American Arbitration Association.Unless the parties agree otherwise the number of arbitrators will be three, each of whom will be appointed by the American Arbitration Association. Onearbitrator must be a lawyer, the second must be an expert in financial matters, and the third must have expertise in the manufacture of hemodialysisproducts. The place of arbitration will be Washington, D.C., U.S.A. The language of the arbitration will be English. Prior to the commencement ofhearings, each of the arbitrators appointed must provide an oath or undertaking of impartiality. Judgment upon the award rendered by the arbitrators maybe entered by any court having jurisdiction thereof. The cost of any such arbitration will be divided equally between Vapotherm, on the one hand, andMedica, on the other hand, with each party bearing its own attorneys’ fees and costs.14.6 Force Majeure. No party will be responsible to the other under this Agreement for failure or delay in performing any obligations under thisAgreement, other than payment obligations, due to factors beyond its control, including without limitation any war, fire, earthquake, or other naturalcatastrophe, or any act of God, but excluding labor disputes involving all or any part of the work force of that party (each such factor, an “Event of ForceMajeure”). Upon the occurrence of an Event of Force Majeure, the party failing or delaying performance shall promptly notify the other party in writing,setting forth the nature of the occurrence, its expected duration, and how that party’s performance is affected. Any party subject to an Event of ForceMajeure shall use commercially reasonable efforts to resume performing its obligations under this Agreement as soon as practicable. Except as providedin Section 14.6(b), if an Event of Force Majeure occurs, the affected party’ will be excused from performing and the time for performance will be extendedas long as that party is unable to perform as result of the Event of Force Majeure.(b) If any Event of Force Majeure prevents Medica from delivering any shipment of Cartridges for more than [ ] Business Days beyondthe scheduled delivery date, then Vapotherm may cancel its order without incurring any liability to Medica with respect thereto.14.7 Assignment. This Agreement inures to the benefit of and is binding upon the successors and assignees of the parties. Neither party mayassign any of its rights or obligations under this Agreement without the prior written consent of the other except that: (1) Vapotherm may assign thisAgreement or transfer its rights and obligations under this Agreement to an Affiliate of Vapotherm or a successor to all or substantially all of its assets orbusiness relating to this-Agreement, whether by sale, merger, operation of law, or otherwise.14.8 Notices. Every notice or other communication required or contemplated by this Agreement must be in writing and sent by one of the followingmethods:(1)personal delivery, in which case delivery will be deemed to occur the day of delivery;-22-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.(2)by a recognized overnight delivery service such as Federal Express or DHL Worldwide Express, in which case delivery will be deemed tooccur the day of delivery.(b) In each case, a notice or other communication sent to a party must be directed to the address for that party set forth below, or to anotheraddress designated by that party by written notice. All notices to be given by a Medica Entity may be given on its behalf by the other Medica Entityfollowing consultation between Medica. If to:Vapotherm Inc.198 Log Canoe CircleStevensville MD 21666Attention: CFOwith a copy to:Hogan Hartson L.L.P.555 13th Street, N.W., Washington, D.C. 20004-1009Attention: Stephen J. Zempolich, Esq.if to Medica:Medica S.p.A.Via Degli Artigiani, 741036 Medolla (MO) ItalyAttention: Luciano Fecondini14.9 Severability. If any provision of this Agreement is held unenforceable by any court of competent jurisdiction, all other provisions of thisAgreement will remain effective. If any provision of this Agreement is held to be unenforceable only in part or degree, it will remain effective to the extentnot held unenforceable.14.10 Entire Agreement. This Agreement constitutes the entire agreement of the parties pertaining to the subject matter of this Agreement. Itsupersedes all prior agreements of the parties, whether oral or written, pertaining to the subject matter of this Agreement.14.11 Amendment. This Agreement may not be amended except by an instrument in writing signed on behalf of both parties.14.12 Independent Contractor. Nothing in this Agreement creates, or will be deemed to create, a partnership or the relationship of principal andagent or employer and employee between the parties. Each party agrees to perform under this Agreement solely as an independent contractor,14.13 Counterparts. This Agreement may be executed in counterparts, each of which is an original and all of which together constitute one and thesame instrument.-23-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.14.14 Compliance with Laws. Vapotherm and Medica shall each comply in all material respects with all applicable Laws that pertain to the activitiesfor which Vapotherm and Medica are each responsible under this Agreement and, except as provided for herein, shall bear their own cost and expense ofcomplying therewith.-24-[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.IN WITNESS WHEREOF, each of the undersigned have caused this Manufacturing and Supply Agreement to be duly executed and delivered intheir name and on their behalf as of the date first set forth above.VAPOTHERM, INC.By: /s/ Joseph ArmyName: Joseph ArmyTitle: President CEOMEDICA S.p.ABy: /s/ Luciano FecondiniName: Luciano FecondiniTitle: Amministratore Unico[ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.Exhibit A-1 Price Schedule: in EURO (Euro)[ ]Exhibit A-2: Forecast[ ][ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.Exhibit B: Purchase Order Form Example[ ][ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.Exhibit C Vapotherm Tools[ ][ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.Exhibit D: [ ] Purchase Specifications[ ][ ] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities andExchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.